Loading
Sorrento Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Ji Henry, was filed 07 Sept 2022.
Sorrento Therapeutics, Inc.: what insiders have been doing
Sorrento Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Nothing new has been filed by managers of Sorrento Therapeutics, Inc. in twelve months, the latest record being from 20 March 2023.
Our records for Sorrento Therapeutics, Inc. go back to 2007, with 68 purchases and 48 sales on the open market in total.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
169
Thresholds
n/a
Buy Volume
€11M
68 ops. · all time
Sell Volume
€14M
48 ops. · all time
Since the insiders bought
- -90.1%Entry US$2.37 · Close at T+365 US$0.23
- -72.6%Entry US$7.55 · Close at T+365 US$2.07
- +265.0%Entry US$2.00 · Close at T+365 US$7.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$62.8M
Gross profitUS$29.4M47% margin
EBITDA-US$539.9M-859% margin
Net income-US$572.8M-911.6% margin
Valuation
Beta-0.01
Balance sheet & cash
Total debtUS$134.5M
Free Cash Flow-US$307.5M
Profitability & ownership
ROA-40.8%
% institutions0.0%
Last declaration on 20 March 2023
Declarations169 total
19,500 shares@ US$0.80273.1% of flowCommon StockSEC:0000899243-23-009159:0
300 shares@ US$5.50Common StockSEC:0001209191-22-062586:1
200 shares@ US$5.500.2% of flowCommon StockSEC:0001209191-22-062586:0
1,500,000 shares0Common StockSEC:0001209191-22-061746:0
88,888 shares@ US$2.017738.2% of flowCommon StockSEC:0001209191-22-049065:0
Canonical exit: 6 Dec 2022 (T+90)
55,555 shares@ US$1.959923.4% of flowCommon StockSEC:0001209191-22-048811:0
Canonical exit: 5 Dec 2022 (T+90)
2,500,000 shares0Common StockSEC:0001209191-22-048514:0
33,333 shares@ US$2.1115.0% of flowCommon StockSEC:0001209191-22-047741:0
Canonical exit: 24 Nov 2022 (T+90)
22,222 shares@ US$2.05969.8% of flowCommon StockSEC:0001209191-22-047558:0
Canonical exit: 23 Nov 2022 (T+90)
10,000 shares@ US$1.39992.9% of flowCommon StockSEC:0001209191-22-036760:0
Canonical exit: 12 Sept 2022 (T+90)
3,000 shares@ US$5.880.0% of flowCommon StockSEC:0001209191-21-071311:1
3,000 shares@ US$4.0012.0% of flowCommon StockSEC:0001209191-21-071311:0
10,000 shares@ US$4.007.3% of flowCommon StockSEC:0001209191-21-058036:0
7,357 shares@ US$3.570.0% of flowCommon StockSEC:0001209191-21-057957:1
42,357 shares@ US$8.020.0% of flowCommon StockSEC:0001209191-21-057957:2
35,000 shares@ US$1.8061.1% of flowCommon StockSEC:0001209191-21-057957:0
8,000 shares@ US$8.040.0% of flowCommon StockSEC:0001209191-21-055954:1
8,000 shares@ US$3.5026.9% of flowCommon StockSEC:0001209191-21-055954:0
100,000 shares@ US$4.89Common StockSEC:0001209191-21-054841:1
75,000 shares@ US$3.95100.0% of flowCommon StockSEC:0001209191-21-054841:0
1,900 shares@ US$3.500.0% of flowCommon StockSEC:0001209191-21-026867:0
1,900 shares@ US$6.97Common StockSEC:0001209191-21-026867:1
56,974 shares0Common StockSEC:0001209191-21-021394:0
1,000 shares0Common StockSEC:0001209191-21-005470:0
1,000 shares@ US$7.14Common StockSEC:0001209191-21-005470:1
25 of 169 declarations
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. The company traces its roots to 2006, when it was originally incorporated in California as San Diego Antibody Company, before adopting the Sorrento Therapeutics name and reincorporating in Delaware in 2009. Its historical headquarters and principal operating base have been in San Diego, California, which has remained central to its corporate identity and life-sciences footprint.([sec.gov](https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm?utm_source=openai))
Sorrento has long positioned itself as an antibody-centric, clinical-stage and commercial-stage biotech focused on innovative therapies for high-unmet-need indications. Its core R&D strategy has revolved around proprietary platforms such as the G-MAB™ fully human antibody library, targeted delivery modalities, immuno-cellular therapies including DAR-T™ and CAR-T concepts, antibody-drug conjugates (ADCs), and oncolytic virus programs such as Seprehvec™. Over time, the company has also discussed pipeline efforts in cancer, pain, autoimmune disease, infectious disease, and coronavirus-related programs, including diagnostic and antiviral initiatives. That breadth gives Sorrento scientific optionality, but it also reflects the complexity and execution risk of a platform-driven biotech model.([sec.gov](https://www.sec.gov/Archives/edgar/data/850261/000156459021006983/srne-10k_20201231.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Sorrento operates in one of the most crowded and capital-intensive segments of healthcare. Its differentiation has historically been based on combining multiple therapeutic modalities rather than relying on a single lead asset. However, the company’s recent history has been dominated by restructuring rather than product commercialization. A key recent development was the September 2023 sale of substantially all Scilex securities held by Sorrento; following that transaction, Sorrento no longer controlled Scilex, and Scilex was deconsolidated from Sorrento’s financial statements as discontinued operations. The transaction also took place in the context of Sorrento’s Chapter 11 proceedings, underscoring that the equity story is closely tied to balance-sheet repair, asset monetization, and legal restructuring.([sec.gov](https://www.sec.gov/Archives/edgar/data/850261/000110465923103911/tm2326887d1_ex99-2.htm))
Geographically, Sorrento’s presence is primarily U.S.-centric, with its operational and historical base in California. For investors in France, Belgium, and Switzerland, SRNE should therefore be viewed as a special-situation healthcare name on the NASDAQ, not a stable dividend payer or mature pharma franchise. The investment case is driven by binary clinical/regulatory outcomes, restructuring milestones, and potential value realization from legacy assets. In short, Sorrento is a highly speculative U.S. biotech with a broad scientific platform, a long development history, and a recent corporate narrative shaped by deconsolidation, bankruptcy proceedings, and asset rationalization.([sec.gov](https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm?utm_source=openai))
